Table 3 Prevalence and incidence of anti-PF4 antibodies following COVID-19 vaccination
Author | Laboratory assay | Prevalence | Seroconversion | Type of vaccine |
|---|---|---|---|---|
Ingvild(9) | Lifecodes PF4 IgG ELISA immunoassay (Immucor, Waukesha, WI) | 6/492 (1.2%) | Not reported | ChAdOx1 |
Thiele(4) | In-house IgG- specific PF4/polyanion EIA | 11/138 (8%) 8/143 (5.6%) | 2/138 (1.4%) 2/143 (1.4%) | ChAdOx1 BNT162b2 |
Uaprasert(10) | Zymutest HIA IgG (Hyphen Biomed, Neuville-sur-Oise, France) | 16/521 (3.1%) | Not reported | ChAdOx1 |
Noikongdee(3) | Zymutest HIA IgG (Hyphen Biomed Zymutest HIA IgG; Quadratech Diagnostics, Surrey, United Kingdom) | 5/221 (2.3%) 4/ 232 (1.7%) | Not reported | ChAdOx1 CoronaVac |
Terpos(11) | ELISA (Asserachrom, Stago, Vienna, Austria) | 29/43 (67%) | Not reported | ChAdOx1 |
Hantrakun(12) | Zymutest HIA, IgG ELISA (Hyphen BioMed, Neuville-sur-Oise, France) | 10/396 (2.5%) | 2/396 (0.5%) | ChAdOx1 |
In this study | Zymutest HIA IgG (Hyphen Biomed Zymutest HIA IgG; Quadratech Diagnostics, Surrey, United Kingdom) | 14 (1.9%) | 3/720 (0.42%) | ChAdOx1 |